U.S. agency says it advised Mylan that EpiPen was misclassified

WASHINGTON (Reuters) - A U.S. health agency said on Wednesday it had "expressly advised" Mylan that the company had misclassified the EpiPen in a way that led to the company paying a lower rebate to states.